Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Fortive is a diversified industrial technology conglomerate operating through two primary segments: Intelligent Operating Solutions (precision instruments, sensors, workflow software for manufacturing and healthcare) and Precision Technologies (advanced instrumentation for electronics, industrial automation, and transportation). The company serves mission-critical applications across manufacturing, healthcare, and transportation end-markets with high-margin software and instrumentation products. The sharp revenue decline (-33.3% YoY) likely reflects portfolio restructuring or divestitures rather than organic deterioration, given the maintained 63.5% gross margin and strong FCF generation.
Fortive monetizes through a razor-and-blade model combining high-margin instrumentation hardware sales with recurring software subscriptions and service contracts. The company leverages the Fortive Business System (FBS) - a continuous improvement methodology similar to Danaher's DBS - to drive operational efficiency and margin expansion. Pricing power stems from mission-critical applications where downtime costs far exceed equipment costs (e.g., semiconductor fab instrumentation, hospital sterilization monitoring). The 63.5% gross margin reflects software mix, proprietary technology, and embedded customer relationships requiring minimal switching incentives.
Industrial capex cycles and manufacturing PMI trends - directly impacts instrumentation demand from factory automation and semiconductor equipment customers
Healthcare capital equipment spending - affects diagnostic and sterilization monitoring product sales to hospitals and labs
Software ARR growth and recurring revenue mix expansion - drives valuation multiple expansion as investors reward predictable cash flows
M&A activity and portfolio optimization - Fortive has history of strategic divestitures (spun off Vontier in 2020) and tuck-in acquisitions to improve margin profile
Semiconductor industry capex cycles - precision measurement tools are critical for advanced node manufacturing
Technological disruption from lower-cost Asian instrumentation manufacturers (particularly Chinese competitors in industrial automation) eroding pricing power in commodity measurement categories
Semiconductor industry consolidation reducing customer count and increasing pricing pressure on metrology equipment suppliers
Healthcare reimbursement pressures limiting hospital capital budgets for diagnostic and monitoring equipment upgrades
Competition from larger diversified peers (Danaher, Roper Technologies) with deeper R&D budgets and broader product portfolios for cross-selling
Software platform competition from pure-play industrial IoT providers (PTC, Rockwell) offering integrated manufacturing execution systems
Private equity-backed instrumentation roll-ups consolidating fragmented niches and competing on price
Current ratio of 0.71 indicates tight working capital management with limited liquidity cushion if receivables extend or inventory builds
The -33.3% revenue decline with only -26.3% EPS decline suggests potential one-time gains or cost cuts masking underlying margin pressure
Moderate debt load (0.50 D/E) manageable but limits M&A flexibility without equity dilution in current market environment
moderate-to-high - Industrial instrumentation demand correlates strongly with manufacturing capex cycles and industrial production. Semiconductor equipment exposure creates leverage to global chip demand cycles. However, healthcare diagnostics and essential infrastructure monitoring provide counter-cyclical stability. The 0.71 current ratio suggests working capital efficiency but limited liquidity buffer during downturns.
Rising rates create headwinds through three channels: (1) customer capex deferrals as financing costs increase for equipment purchases, (2) valuation multiple compression on the high-margin software business (currently trading at 3.5x sales), and (3) modest increase in debt servicing costs on the 0.50 D/E ratio. However, strong FCF generation ($1.0B annually) provides flexibility to manage balance sheet.
Moderate - Industrial customers typically finance large instrumentation purchases, so tighter credit conditions reduce order rates. Healthcare customers are less credit-sensitive due to regulatory requirements for monitoring equipment. The company itself maintains investment-grade credit profile with manageable 0.50 D/E ratio.
value-oriented quality investors - The 6.4% FCF yield, 63.5% gross margin, and strong cash generation attract value investors seeking mispriced quality assets. The recent -16.0% one-year return despite strong recent momentum (16.8% six-month return) suggests the market is re-rating the stock after portfolio restructuring. Not a growth story given negative revenue growth, but the margin profile and FBS operational discipline appeal to investors seeking Danaher-like compounders at discounted valuations.
moderate - Industrial technology stocks typically exhibit beta of 1.0-1.3 to broader markets, with additional volatility from semiconductor cycle exposure. The diversified portfolio across manufacturing, healthcare, and transportation dampens single-industry risk. Recent 10.1% three-month return vs -16.0% one-year return indicates elevated volatility during portfolio transition period.
